SciDev (SDV.AX) Net Debt 2026-03-04 dieną.
SciDev Net Debt
Net Debt
0AUD
Paskutinį kartą atnaujinta: 2026-03-04
SciDev Net Debt yra 2026 0 AUD. SciDev Net Debt buvo 2025 0 AUD. Tai sumažėjo % mažesnis lyginant su praėjusiais metais.
SciDev Akcijų analizė
Ką veikia SciDev? Scidev Ltd is a British corporation specializing in the development and production of products aimed at sustainably improving the quality of life for people in developing countries. The company is headquartered in Wallsend, near Newcastle-upon-Tyne.
Scidev began with a modest budget of only 500 British pounds. The founders, Dr. David Fulford and Dr. Andrew Thompson, aimed to develop cost-effective solutions to address the problem of water scarcity in India and other developing countries. They started by developing simple water treatment technologies and worked closely with engineers and scientists from the region to perfect their technologies. Their first major success was the development and sale of water filters used in rural areas of India.
Today, Scidev is a leading provider of products and solutions in the areas of water technology, health, agriculture, and renewable energy. The company has over 60 employees in the UK and subsidiaries in Switzerland, Kenya, and India.
Scidev's business model is based on the principle that the needs of people in developing countries are best understood by locally-based companies. Scidev works closely with local engineers, scientists, and entrepreneurs to develop innovative solutions that meet the needs of their communities. The company provides training and support to its partners in product launch to ensure their products have a measurable impact on people's lives.
One of Scidev's most successful divisions is water technology. The company offers a range of water purification systems tailored to different conditions and requirements. These include both low-cost systems like the Puddle Pump, which is particularly used in rural areas, and high-tech systems like the membrane filter, which is used in urban areas.
Scidev also develops technologies in the health sector. An example is the immunochromatographic rapid test (ICT), used in the diagnosis and monitoring of diseases such as malaria, HIV, and tuberculosis. The ICT tests allow medical personnel to make quick and cost-effective diagnoses and track the success of treatments.
In the agriculture division, Scidev offers solutions that enable farmers to increase their yields while protecting the environment. One example is the Biolizer XE, an organic-based fertilizer that provides a sustainable alternative to chemical fertilizers. The Biolizer XE was introduced in Kenya and has helped increase farmers' yields while reducing environmental impact from the use of chemical fertilizers.
Scidev is also active in the development of renewable energy. The company has developed a range of products based on solar technology, such as solar lanterns and small solar networks. These products are particularly popular in rural areas where access to electricity is limited.
Overall, Scidev is a company dedicated to improving the quality of life for people in developing countries. The company has successfully developed innovative technologies that address the challenges in these countries while providing viable business models. Scidev has established itself as a pioneer in the development of technologies that have a positive impact on people's lives. SciDev yra viena populiariausių kompanijų Eulerpool.com.
Dažniausiai užduodami klausimai apie SciDev akciją
Eulerpool rasite visą Net Debt SciDev istorinę raidą nuo 2006 m. – su metinėmis reikšmėmis, grafikais ir išsamiomis analizėmis.
Balance Sheet — SciDev
Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsNuosavas kapitalasĮsipareigojimaiĮsiskolinimasCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets
Akcijų taupymo planai siūlo patrauklią galimybę investuotojams ilgalaikėje perspektyvoje kurti turtą. Vienas pagrindinių privalumų yra vadinamasis vidutinės išlaidos efektas: reguliariai investuojant fiksuotą sumą į akcijas arba akcijų fondus, automatiškai perkama daugiau dalinių vertybių popierių, kai kainos yra žemos, ir mažiau – kai jos aukštos. Tai gali lemti palankesnę vidutinę dalies kainą per laiką. Be to, akcijų taupymo planai suteikia galimybę ir smulkiesiems investuotojams patekti į brangias akcijas, nes jie gali dalyvauti jau su mažomis sumomis. Reguliarus investavimas taip pat skatina disciplinuotą investavimo strategiją ir padeda išvengti emociškai pagrįstų sprendimų, pavyzdžiui, impulsyvaus pirkimo ar pardavimo. Be to, investuotojai gauna naudos iš potencialaus akcijų vertės augimo bei iš dividendų, kurie gali būti reinvestuoti, kas sustiprina sudėtinio palūkanų efektą ir taip skatina investuoto kapitalo augimą.
All Key Metrics — SciDev
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Nuosavas kapitalas
- Įsipareigojimai
- Įsiskolinimas
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth